Type 2 diabetes
Conditions
Interventions
DPP-4 inhibitors group:DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin)
GLP-1 receptor agonists group:GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide)
SGLT-2 inhibitor group:SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Sponsors
Shanghai Minhang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients who met the 1999 who diagnostic criteria for diabetes mellitus. Patients with symptoms had fasting blood glucose (FPG) >=7.0 mmol/L or 2-hour postprandial blood glucose >=11.1 mmol/L; those without typical symptoms should have blood glucose >=11.1 mmol/L at 2 hours after oral glucose tolerance test (OGTT), or FPG twice or 2 hours postprandial blood glucose higher than who standard; 2. Patients who initially used DPP-4 inhibitor, GLP-1 receptor agonist or sglt-2 inhibitor for monotherapy, or as additional drugs, combined with metformin or sulfonylurea hypoglycemic agents; 3. Conscious patients who can understand the nature of Chinese version of DQOL; 4. The patients who signed the informed consent of patients and voluntarily participated in the trial; 5. Patients over 18 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with diabetes who can effectively control their blood glucose only through exercise, diet adjustment, metformin or sulfonylurea antidiabetic drugs alone; 2. Patients with diabetes who have not used any one or more DPP-4 inhibitors, GLP-1 receptor agonists or sglt-2 inhibitors, or with other types of hypoglycemic drugs (such as alpha- glucosidase inhibitors, thiazolidinediones, glinides, etc.) in addition to metformin and sulfonylureas; 3. Patients with insulin and type 1 diabetes mellitus; 4. Patients with a history of severe infection and trauma, or patients with severe organ disease, consciousness or cognitive impairment, mental illness, pregnancy or lactation; 5. Patients who are unable or unwilling to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scale score of DQoL; | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c;Fasting plasma glucose;BMI Index; | — |
Countries
China
Contacts
Public ContactJialin Yang
Shanghai Minhang Hospital
Outcome results
None listed